

ADVANCED THERAPIES INVESTMENT REPORT 2017

1

CHAPTER ONE


Overview of the advanced therapies industry



CAR-T market is forecast to be worth

\$8.6bn

by 2028



CAR-T VC funding to date:

\$584m



CAR-T IPOs to date:

\$962m

CHAPTER TWO

Understanding cell and gene therapy pipelines



Insight into clinical trial design and global regulatory approval pathways




A comparative analysis of the EMA's alternative licensing pathways PRIME and 'adaptive pathways'

2

3

CHAPTER THREE

Building value for cell and gene therapies and establishing market access pathways



Scale of market authorised ATMP prices



NICE appraisal of a CAR-T therapy

CHAPTER FOUR

Understanding cell and gene therapy pipelines



Risk analysis of centralised and decentralised manufacturing models



Manufacturing investments since 2016

4

5

CHAPTER FIVE

Understanding biopharma interest



An overview of collaborations between big pharma, biotechs and academia

CHAPTER SIX

Advice for investors

Top questions investors should ask to better understand:

- Product and process development
- Clinical trial design
- Commercial
- Manufacturing and supply chain
- Pricing and reimbursement
- Product and process development

6

For the full insight and analysis on investing in advanced therapies, download the report.

[VIEW REPORT](#)